Vaniqa

RSS

eflornithine

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Vaniqa. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Vaniqa.

This EPAR was last updated on 15/04/2019

Authorisation details

Product details
Name
Vaniqa
Agency product number
EMEA/H/C/000325
Active substance
Eflornithine
International non-proprietary name (INN) or common name
eflornithine
Therapeutic area (MeSH)
Hirsutism
Anatomical therapeutic chemical (ATC) code
D11AX
Publication details
Marketing-authorisation holder
Almirall, S.A.
Revision
22
Date of issue of marketing authorisation valid throughout the European Union
19/03/2001
Contact address
Ronda General Mitre, 151
ES-08022 Barcelona
Spain

Product information

06/03/2019 Vaniqa - EMEA/H/C/000325 - N/0053

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

OTHER DERMATOLOGICAL PREPARATIONS

Therapeutic indication

Treatment of facial hirsutism in women.

Assessment history

How useful was this page?

Add your rating
Average
2 ratings